Pegaptanib: In exudative age-related macular degeneration

Drugs

Volumn 65, Issue 11, 2005, Pages 1571-1577

  Siddiqui, M Asif A ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PEGAPTANIB;

ADULT; ANGIOGRAPHY; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; BLEEDING; BLINDNESS; CATARACTOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; HUMAN; HYPERTENSION; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LENS DISEASE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VISUAL ACUITY;

ANIMALS; APTAMERS, NUCLEOTIDE; HUMANS; INJECTIONS; MACULAR DEGENERATION; OLIGONUCLEOTIDES; RANDOMIZED CONTROLLED TRIALS; VISUAL ACUITY; VITREOUS BODY;

EID: 23744463076     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565110-00010     Document Type: Review

References (21)

1. Hooper CY, Guymer RH. New treatments in age-related macular degeneration. Clin Experiment Ophthalmol 2003; 31 (5): 376-91
2. Kim RW, Heier JS. Innovative treatments for exudative age-related macular degeneration. Int Ophthalmol Clin 2004; 44 (4): 41-50
3. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003; 121 (11): 1621-4
4. Bressler NM. Age-related macular degeneration is the leading cause of blindness.... JAMA 2004; 291 (15): 1900-1
5. Comer GM, Ciulla TA, Criswell MH, et al. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004; 21 (15): 967-92
6. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004; 44 (4): 17-39
7. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122 (4): 564-72
8. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109 (8): 1109-14
9. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 random ized clinical trials - TAP report. Arch Ophthalmol 1999; 117 (10): 1329-45
10. Singerman LJ, for the Macugen Diabetic Retinopathy Study Group. Safety and efficacy of pegaptanib sodium (Macugen™) in patients with diabetic macular edema: results of the phase 2 trial [abstract]. The 28th Annual Macula Society Meeting; 2005 Feb 23-26; Key Biscayne, FL
11. 165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999; 35 (9): 533-42
12. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002 Apr; 22: 143-52
13. Robinson CJ, Stringer SE. The splice variants of vascular endo-thelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114 (5): 853-65
14. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157 (1): 135-44
15. Guyer DR, Fish G, Haller JA, et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110 (5): 979-86
16. Eyetech Pharmaceuticals Inc./Pfizer Inc. Product information: Macugen® (pegaptanib sodium injection) 0.3mg [online]. Available from URL: http://www.macugen.com [Accessed 2005 Jun 8]
17. Capone A, for the Macugen AMD Study Group. Safety and pharmacokinetics of intravitreous pegaptanib sodium (Macugen®) in patients with exudative age-related macular degeneration (AMD) [abstract]. The 28th Annual Macula Society Meeting; 2005 Feb 23-26; Key Biscayne, FL
18. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000 Dec; 17: 1503-10
19. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 Dec 30; 351 (27): 2805-16
20. D'Amico DJ, for the VEGF inhibition study in ocular neovascu larisation (VISION) clinical trials group. Second year efficacy data from the VISION study [abstract]. The 28th Annual Macula Society Meeting; 2005 Feb 23-26; Key Biscayne, FL
21. Mieler WF, for the VEGF inhibition study in ocular neovascularisation (VISION) clinical trials group. VEGF inhibition study in ocular neovascularisation (VISION): safety assessment of second year treatment with Macugen™ (pegaptanib sodium) for AMD [abstract]. The 28th Annual Macula Society Meeting; 2005 Feb 23-26; Key Biscayne, FL